CAJ | 학술논문

目的：研究三磷酸腺苷-肿瘤体外药敏试验(ATP-tumor chemosensitivity assay，ATP-TCA)对宫颈癌患者化学治疗(化疗)方案选择的指导性作用。方法：选择2007年7月至2009年10月宫颈癌住院患者72例，将其随机分为药敏组(35例)和对照组(37)例。采用ATP-TCA法检测药敏组宫颈癌组织对6种联合化疗方案的敏感性。药敏组患者根据药敏结果选择化疗方案，对照组根据临床经验制定化疗方案。随访3年，比较药敏组与对照组1年复发率和3年生存率。结果：35例药敏组中有32例成功进行了ATP-TCA检测；体外有效例数分别为紫杉醇+卡铂20例、紫杉醇+奥沙利铂18例、博莱霉素+异环磷酰胺+顺铂17例、博莱霉素+长春新碱+顺铂18例、氟尿嘧啶+顺铂17例、吉西他滨+顺铂21例。1年复发例数药敏组与对照组比较差异无统计学意义(P>0.05)；3年生存情况药敏组好于对照组(P<0.05)。结论：ATP-TCA法可以为宫颈癌患者筛选出敏感、有效、个体化的化疗方案，值得临床推广。
목적：연구삼린산선감-종류체외약민시험(ATP-tumor chemosensitivity assay，ATP-TCA)대궁경암환자화학치료(화료)방안선택적지도성작용。방법：선택2007년7월지2009년10월궁경암주원환자72례，장기수궤분위약민조(35례)화대조조(37)례。채용ATP-TCA법검측약민조궁경암조직대6충연합화료방안적민감성。약민조환자근거약민결과선택화료방안，대조조근거림상경험제정화료방안。수방3년，비교약민조여대조조1년복발솔화3년생존솔。결과：35례약민조중유32례성공진행료ATP-TCA검측；체외유효례수분별위자삼순+잡박20례、자삼순+오사리박18례、박래매소+이배린선알+순박17례、박래매소+장춘신감+순박18례、불뇨밀정+순박17례、길서타빈+순박21례。1년복발례수약민조여대조조비교차이무통계학의의(P>0.05)；3년생존정황약민조호우대조조(P<0.05)。결론：ATP-TCA법가이위궁경암환자사선출민감、유효、개체화적화료방안，치득림상추엄。
Objective:To select suitable chemotherapy for cervical cancer patients by ATP-tumor chemosensitivity assay. <br> Methods:Seventy-two hospitalized patients with cervical cancer between July 2007 and October 2009 were enrolled. The patients were randomly divided into a trial group (n=35) and a control group(n=37). ATP-TCA was used to detect the sensitivity of 35 samples of cervical cancer in the trial group to 6 combined chemotherapy regimens. The chemotherapy regimen in the trial group was confirmed by the results of susceptibility testing and that in the control group was confirmed by clinical experience. One-year recurrence rate and 3-year survival rate of two groups were compared after 3 year follow-up. <br> Results:ATP-TCA was measured in 32 of the 35 patients in the trial group. The sensitive patients for paclitaxel+carboplatin, paclitaxel+oxaliplatin, bleomycin+ifosfamide+cisplatin, bleomycin+vincristine+cisplatin, fluorouracil+cisplatin, and gemcitabine+cisplatin were 20, 18, 17, 18, 17, and 21, respectively. There was no significant difference in the 1-year recurrence between the two groups (P>0.05), while the 3-year survivors in the trial group were more than those in the control group (P<0.05). <br> Conclusion:ATP-TCA method is good for patients with cervical cancer because it is sensitive, effective, and individualized.